Johnson & Johnson Inc said that its single-shot vaccine against Covid-19 was 66% effective in preventing moderate to severe disease following a Phase 3 trial that included participants from the US, South Africa and countries in Latin America. ---Subscribe to MedNous to access this article--- Clinical Research Company News
